Literature DB >> 9627112

Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas.

A M Burger1, X Zhang, H Li, J L Ostrowski, B Beatty, M Venanzoni, T Papas, A Seth.   

Abstract

To define genes that are essential to the initiation and progression of breast cancer we utilized subtractive hybridization and differential display cloning techniques and isolated over 950 cDNAs from breast cell-lines derived from matched normal and tumor tissue. Of these, 102 cDNAs were characterized by DNA sequencing and Northern blot analysis. GenBank searches showed that one of these genes, T1A12 is identical to mac25, an insulin-like growth factor-binding protein related gene. Antibodies generated against the C-terminal region of the T1A12/mac25 protein were used to investigate its expression in 60 primary breast tissues. Sections of 12 benign, 16 ductal carcinoma in situ and 32 infiltrating ductal carcinoma specimens were examined. Strong immunoperoxidase staining was observed in luminal epithelial cells of normal lobules and ducts, in apocrine cells of cysts and fibroadenomas. Moderate to weak protein expression was found in hyperplastic and DCIS cells, but no specific staining was detected in invasive carcinoma cells. FISH mapping using a PAC clone localized the T1A12/mac25 gene to 4q12-13. Microsatellite length polymorphism was studied using markers for 4q in paired normal and tumor breast tissues. Thirty-three per cent (10/30) of the samples were found to be polymorphic with D4S189 and D4S231 microsatellite markers and LOH was detected in 50% (5/10) of these informative samples. Our data indicate that T1A12/mac25 expression is abrogated during breast cancer progression concomitant with loss of heterozygosity on chromosome 4q. T1A12/mac25 may therefore have a tumor suppressor-like function and its expression could indicate a disease with a more favorable status, having a better prognosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627112     DOI: 10.1038/sj.onc.1201772

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

Review 1.  Subtractive hybridization--genetic takeaways and the search for meaning.

Authors:  R J Byers; J A Hoyland; J Dixon; A J Freemont
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

Review 2.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

3.  Identification of differentially expressed genes in normal mucosa, adenoma and adenocarcinoma of colon by SSH.

Authors:  M J Luo; M D Lai
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

4.  Expression of IGFBP7 mRNA in corticotrophs in the anterior pituitary of adrenalectomized rats.

Authors:  Takashi Nakakura; Azusa Soda; Keisuke Unno; Masakazu Suzuki; Shigeyasu Tanaka
Journal:  J Histochem Cytochem       Date:  2010-07-19       Impact factor: 2.479

Review 5.  AEG-1/MTDH/LYRIC in liver cancer.

Authors:  Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

6.  The functional IGFBP7 promoter -418G>A polymorphism and risk of head and neck cancer.

Authors:  Yu-Jing Huang; Jiangong Niu; Zhensheng Liu; Li-E Wang; Erich M Sturgis; Qingyi Wei
Journal:  Mutat Res       Date:  2010-07-03       Impact factor: 2.433

7.  Expression of stress-response and cell proliferation genes in renal cell carcinoma induced by oxidative stress.

Authors:  T Tanaka; S Kondo; Y Iwasa; H Hiai; S Toyokuni
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

8.  Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma.

Authors:  Li-Xin Jiang; Jie Xu; Zhao-Wen Wang; Da-Peng Li; Zhi-Hai Peng; Jian-Jun Gao; Lin He; Hai-Tao Zheng
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

9.  Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells.

Authors:  Y Tomimaru; H Eguchi; H Wada; T Noda; M Murakami; S Kobayashi; S Marubashi; Y Takeda; M Tanemura; K Umeshita; Y Doki; M Mori; H Nagano
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

10.  Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC).

Authors:  Dong Chen; Ayesha Siddiq; Luni Emdad; Devaraja Rajasekaran; Rachel Gredler; Xue-Ning Shen; Prasanna K Santhekadur; Jyoti Srivastava; Chadia L Robertson; Igor Dmitriev; Elena A Kashentseva; David T Curiel; Paul B Fisher; Devanand Sarkar
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.